Opinion/decision on a Paediatric investigation plan (PIP): Brukinsa, zanubrutinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0226

Opinion/decision on a Paediatric investigation plan (PIP): Brukinsa, zanubrutinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0226/2024

Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Axura, memantine, Date of authorisation: 17/05/2002, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Axura, memantine, Date of authorisation: 17/05/2002, Revision: 29, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.